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Abstract Oligodendrocytes are the myelinating cells of
the central nervous system (CNS). They are the end
product of a cell lineage which has to undergo a complex
and precisely timed program of proliferation, migration,
differentiation, and myelination to ﬁnally produce the
insulating sheath of axons. Due to this complex differen-
tiation program, and due to their unique metabolism/
physiology, oligodendrocytes count among the most vul-
nerable cells of the CNS. In this review, we ﬁrst describe
the different steps eventually culminating in the formation
of mature oligodendrocytes and myelin sheaths, as they
were revealed by studies in rodents. We will then show
differences and similarities of human oligodendrocyte
development. Finally, we will lay out the different path-
ways leading to oligodendrocyte and myelin loss in human
CNS diseases, and we will reveal the different principles
leading to the restoration of myelin sheaths or to a failure
to do so.
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General introduction
Most of our knowledge about the biology of oligodendro-
cytes and myelin derives from studies in rodents. This fact
can be easily explained, since cells or tissue slices of these
animals are readily available and can be easily cultured,
and since a large number of genetically modiﬁed animals
allows it to dissect the function of individual proteins in the
proper spatial and temporal context of development and
disease. Studies in rodents led to the identiﬁcation of
important principles of oligodendrocyte development and
myelin formation.
The development of oligodendrocytes
and myelin—a rodent’s perspective
Spinal cord and brain contain different subclasses
of oligodendrocytes which derive from multiple sources
In the spinal cord, most oligodendrocytes derive from a
specialized domain of the ventral ventricular zone, which
ﬁrst gives rise to motor neuron precursors, and then, after
the neurogenic/gliogenic switch, to oligodendrocyte pre-
cursor cells/progenitors (OPCs) [107, 181, 183, 214]. From
there, OPCs migrate all through the spinal cord and ﬁnally
differentiate into myelin-forming oligodendrocytes. Later,
an additional source of OPCs arises in the dorsal spinal
cord, contributing to 10–15% of the ﬁnal oligodendrocyte
population in the spinal cord [25, 49, 195].
In the forebrain, the ﬁrst OPCs originate in the medial
ganglionic eminence and anterior entopeduncular area of
the ventral forebrain. These OPCs populate the entire
embryonic telencephalon including the cerebral cortex, and
are then joined by a second wave of OPCs derived from the
lateral and/or caudal ganglionic eminences. The third wave
of OPCs, ﬁnally, arises within the postnatal cortex [86].
These different populations of OPCs are functionally
redundant: When any one of them is destroyed at source
by the targeted expression of a toxin gene in mice, the
remaining cells spread into the vacant territory and restore
the normal distribution of OPCs. As a result of this,
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be produced, and the mice develop, survive, and behave
normally [86]. In spite, or maybe even due to this func-
tional redundancy, the different OPC populations seem to
be ﬁerce competitors.
Different OPC lines compete with each other
during development
In the developing rodent spinal cord, the competition is
won by OPCs derived from the ventral ventricular zone:
These cells represent the ﬁrst wave of cells of the oligo-
dendrocyte lineage generated in the spinal cord, and
eventually give rise to 85–90% of the ﬁnal oligodendrocyte
population found in this organ [25, 49, 195]. In this case,
competition for limiting quantities of growth factors like
platelet-derived growth factor (PDGF) might be a deter-
mining factor for winning the competition [9, 26, 196].
In the developing forebrain, however, the situation
seems to be quite different. Here, the competition is clearly
lost by the ﬁrst wave OPCs: although these cells are the
ﬁrst to distribute and to occupy vacant territories, their
contribution to the total OPC population rapidly declines,
until they are almost completely eliminated from the adult
forebrain.
The reasons for the eventual loss of one OPC population
in the developing forebrain remain completely unclear, and
one can only speculate about possible causes and conse-
quences [157].
According to such speculations, the ﬁrst wave of fore-
brain OPCs emerging from the medial ganglionic eminence
and the anterior entopeduncular area might represent the
most ‘‘primitive source’’ of oligodendrocytes, a relic that
lost its importance during evolution, when new sources of
OPCs developed in the expanding brain. This assumption is
supported by the observation that birds, which have much
less cortical volume than mammals derive their OPCs only
from the anterior entopeduncular area [157]. Alternatively,
the ﬁrst wave OPCs could be lost in the course of a (not yet
demonstrated) oligodendrocyte turnover, or as a result of
changes in the availability/responsiveness to growth and
differentiation factors. Moreover, they might become dis-
pensable if they have functions during development, that
are not required in the adult [157].
No matter whether OPCs belong to the ﬁrst, second, or
third wave of cells, they have one point in common: They
have to travel long distances in order to end up in their ﬁnal
place of destination. This migration is tightly controlled.
OPC migration is guided by regulatory signals
To date, three different classes of secreted molecules seem
to be involved in the migration of OPCs: growth factors
like PDGF, FGF [155, 174] or hepatocyte growth factor
[211, 138]; chemotropic molecules like netrins and secre-
ted semaphorins [74, 193]; and the chemokine CXCL1
[37]. Although there is no doubt that these factors play a
role in OPC migration, the exact mode of action of these
factors is still a matter of controversy, in part due to dif-
ferences in experimental models, culture systems, and time
points studied.
OPC migration is not only controlled by secreted mol-
ecules, but is also regulated by contact-mediated
mechanisms involving many different extracellular matrix
proteins and cell surface molecules [52, 88, 199], N-cad-
herins [125, 133, 145, 167, 190], and possibly even
additional, yet unidentiﬁed molecules.
From all these different molecules, a common theme
evolves, demonstrating contact-based migration of OPCs
over extracellular matrices, axonal tracts, and astrocytic
surfaces [37]. Once located at their ﬁnal destination, some
OPCs persist into adulthood (see Appendix 1), while the
vastmajoritydifferentiatestomyelin-producingoligodendro-
cytes.
The differentiation of OPCs to oligodendrocytes
and the onset of myelination are spatially
and temporally regulated
This process involves signaling processes between the
Notch1 receptor, its ligand Jagged 1 located on the axonal
surface [55], and c-secretase [150, 202]. Interestingly,
oligodendrocytes have only a brief period of time for
myelination early during differentiation, and are relatively
incapable of myelinating once they are mature [202].
Moreover, the ensheathment of multiple axons by a single
oligodendrocyte is a highly coordinated event: oligoden-
drocytes do not ensheath different axons sequentially at
different time points, but are done within a brief window of
time, typically within 12–18 h [8, 202].
Oligodendrocytes do not randomly wrap plasma
membrane around neuronal processes
Oligodendrocytes select axons with diameters above
0.2 lm[ 171]. The molecular cues for this recognition
remain unknown. In the peripheral nervous system, the
critical axonal signal for myelination by Schwann cells is
provided by neuronal neuregulin-1 (NRG1) type III,
interacting with glial ErbB receptors, and it was thought for
a long time that NRG1/ErbB signaling might also regulate
myelination in the CNS. This point of view was supported
by the observation that not only Schwann cells, but also
oligodendrocytes express erbB receptors (oligodendrocytes
erbB2 and erbB4, Schwann cells erbB2 and erbB3, but
only little erbB4 [197]). It was further observed, that
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derived from mice lacking neuregulin [198], that erbB2 is
required for the development of terminally differentiated
spinal cord oligodendrocytes [141], and that erbB2 plays a
role in governing the properly timed exit from the cell
cycle during development into myelinating oligodendro-
cytes [89]. Moreover, mice with dominant negative erbB4
have more differentiated oligodendrocytes, but each of
them seems to myelinate less axonal surface and to produce
thinner myelin sheaths than its wild-type counterpart [159].
And last, mice haploinsufﬁcient for type III NRG1 are
hypomyelinated in the brain, and normally myelinated in
the optic nerve and spinal cord [187]. However, recent
observations challenge the assumption that NRG1/ErbB
signaling might also regulate myelination in the CNS.
Instead, they suggest that NRG1/ErbB signaling serves
distinct functions in myelination of the peripheral and
central nervous system [19]: Mice completely lacking
NRG1 beginning at different stages of neural development
assemble normal amounts of myelin, on schedule [19].
When neuregulin signaling is completely abolished in oli-
godendrocytes of double mutants lacking ErbB3 and ErbB4
(and carrying ErbB2 without ligand-binding activity), CNS
axons are nevertheless myelinated without delay, and at the
same level as in control mice, at least until postnatal day
p11, the latest time point studied [19]. However, while
myelination was not delayed even in the absence of NRG1,
there was clear evidence for premature, and even for hyper-
myelination in NRG1 type III overexpressing mice [19].
Cumulatively, these data suggest that normal myelination
occurs independently of NRG1 signaling in vivo. They
also demonstrate that excess NRG1 can initiate the mye-
lination program in CNS development, but that this
function is normally provided by different, still unknown
axonal signaling systems.
Myelination is a regulated process
The data summarized above led to the conclusion that the
onset of CNS myelination in normal development might be
determined by the degree of neuronal differentiation, and
not by the timing of an intrinsic oligodendrocyte differ-
entiation program [19].
One essential signal for the onset of myelination seems
to be provided by the electrical activity of neurons. For
example, the optic nerves of mice which had been reared in
the dark developed fewer myelinated axons than control
optic nerves [62], optic nerves of naturally blind cape-mole
rats are hypomyelinated [139], and blockade of sodium-
dependent action potentials in developing optic nerves
inhibits myelination [38]. Vice versa, increasing neuronal
ﬁring with a-scorpion toxin enhances myelination [38], and
premature eye opening accelerates myelination in rabbit
optic nerves [186]. Action potential ﬁring leads to the
release of ATP [177] and adenosine [96, 115], which can
mediate neuron-glial communications. In the CNS, aden-
osine inhibits the proliferation of OPCs, stimulates their
differentiation, and promotes the formation of myelin
[178]. The ATP released from axons ﬁring axon potentials
does not directly act on OPCs or oligodendrocytes. Instead,
it triggers the release of leukemia inhibitory factor (LIF)
from astrocytes, which promotes myelination by mature
oligodendrocytes [67]. This fact could explain why
LIF-/- mice display impaired myelin formation [23], and
why interfering with astrocyte biology leads to myelin
abnormalities, as seen in mice with knock-out of the
astrocytic protein GFAP [104], and in patients with Alex-
ander disease, a fatal white matter disorder of childhood
caused by mutations in the GFAP gene [124].
Although the electrical activity of neurons in the CNS is
an essential promyelinating factor, additional changes on
axons seem to be needed to drive efﬁcient myelin forma-
tion. Some of these changes seem to be induced by
electrical activity as well. For example, during develop-
ment, all growing nerve ﬁbers express the polysialylated-
neural cell adhesion molecule (PSA-NCAM), which
prevents homophilic NCAM–NCAM adhesion and, more
generally, cell–cell interactions. Only when this form of
NCAM is downregulated, as it is in electrically active
neurons [91, 97], myelination can proceed [32]. Another
molecule correlating with the extent of oligodendrocyte
maturation and myelination is LINGO-1, a transmembrane
protein with leucine-rich repeats and an immunoglobulin
domain expressed in neurons and oligodendrocytes. Loss
of LINGO-1 function in oligodendrocytes leads to
increased myelination, whereas its overexpression inhibits
myelin formation [122].
There are certainly more, yet unidentiﬁed molecular
mechanisms enabling oligodendrocytes to recognize, en-
sheath, and wrap axons [8].
Myelin assembly is under neuronal control
The window of time available for the onset of myelination
seems to be very narrow, in the range of 12–18 h during
which oligodendrocytes have to wrap layer after layer of
plasma membrane around multiple axons [8]. Hence, they
have to synthesize, sort, and trafﬁck an enormous amount
of proteins in short time. The machinery for these processes
is rather complex. For example, one major myelin protein,
myelin basic protein (MBP, Table 1), is targeted by
transport of its mRNA. The MBP mRNA is assembled into
granules in the perikaryon of oligodendrocytes, transported
along processes, and then localized to the myelin mem-
brane [2, 3]. The other major protein, proteolipid protein
(PLP)/DM20 is transported to myelin by vesicular transport
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tions suggest that both delivery systems might be under the
control of neuronal signals.
First, oligodendrocyte cultures without neurons express
MBP, PLP, and galactosylceramide (GalC). However,
under these conditions, PLP is predominantly intracellu-
larly localized, and shows only little co-localization with
MBP or GalC in the membrane sheets. In coculture with
neurons, however, PLP, MBP, and GalC are co-localized.
This rearrangement of the oligodendroglial plasma mem-
brane is critically dependent on the presence of MBP. MBP
seems to act as a lipid coupler by bringing the different
layers of myelin in close position (a process termed ‘‘ver-
tical membrane coupling’’), and by clustering the lipid
bilayer in lateral dimensions (‘‘horizontal membrane cou-
pling’’). This neuron- and MBP-dependent clustering
mechanism might be responsible for the concentration of
membrane components within myelin [48].
Second, in the absence of neurons, PLP is produced by
oligodendrocytes, but immediately internalized by endo-
cytosis. After receiving neuronal signals, the rate of
endocytosis is reduced, and PLP is transported from the late
endosomes/lysosomes to the plasma membrane by exocy-
tosis [192]. This regulation of PLP trafﬁcking might
represent a mechanism to store membrane produced in
advance, before the onset of myelination, and to release this
membrane on demand in a regulated fashion [171] (Fig. 1).
The development of oligodendrocytes
and myelin—what is similar/different in humans?
The key ﬁndings of rodent oligodendrocyte development
and myelin formation described above include: (1) a
common progenitor cell for neurons and oligodendrocytes;
(2) a ventral to dorsal progression of oligodendrogenesis;
(3) multiple origins of oligodendrocytes; (4) the depen-
dency of differentiation and migration on regulatory
factors; and (5) the interrelationship between axonal sig-
naling and myelination.
In general, all these principles seem to apply to the
human system as well, although evidence for it is mostly
circumstantial and beyond the scope of this review to
discuss. Instead, we refer the reader to an excellent review
Table 1 Markers for oligodendrocytes in paraformaldehyde-ﬁxed brain tissue
Protein Developmental stage Comments References
Carbonic anhydrase II Differentiated oligodendrocytes Not only oligodendrocytes interspecies
differences
[15, 87]
CNP OPC, differentiated
oligodendrocytes
Highly speciﬁc and reliable; tolerates prolonged
ﬁxation poorly
[1, 22]
GalC Differentiating OPC, mature
oligodendrocytes
PFA/cryo-sections only [207, 208]
Kir4.1 Differentiated oligodendrocytes Also in astrocytes [77, 132]
MBP Differentiated oligodendrocytes Mainly myelin, in oligodendrocytes only during
active remyelination
[1, 22]
MAG Differentiated oligodendrocytes Periaxonal loop of oligodendrocyte processes in
mature myelin, heavily expressed in
myelinating oligodendrocytes
[1]
MOG Differentiated oligodendrocytes Mainly myelin, surface labeling of mature
oligodendrocytes
[1, 22]
NG2 OPC PFA/cryo; positive in OPCs in well ﬁxed
experimental and biopsy material; frequently
lost in autopsy material; autolysis sensitive
[85]
Nkx2.2 High in OPC, low in mature
oligodendrocytes
[94]
Nogo A Mature oligodendrocytes [94]
O4 OPC, mature oligodendrocytes PFA/cryo-sections only [207]
Olig2 High in OPC, low in mature
oligodendrocytes
[94]
PLP Differentiated oligodendrocytes Mainly myelin, in oligodendrocytes only during
active remyelination
[143]
RIP Myelinating oligodendrocytes [13]
TPPP/p25 Myelinating oligodendrocytes Mature oligodendrocytes, highly reliable in
human tissue
[58, 146]
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123Fig. 1 a–d Detection of oligodendrocytes in parafﬁn embedded
tissue sections. a Mouse cortex, stained by immunocytochemistry for
CNPase shows numerous process bearing oligodendrocytes and
staining of myelin sheaths, 9120; b high magniﬁcation of a CNPase
positive oligodendrocyte in the mouse cortex (layer I), showing a
small round cell body and few cell processes connected to myelin
sheaths, 91,000; c rat spinal cord stained by in situ hybridization for
myelin basic protein mRNA; staining is seen in the cell bodies (e.g.,
in the gray matter) as well as in oligodendrocyte processes associated
with myelin sheaths (dark staining in the white matter), 950; d rat
spinal cord stained by in situ hybridization for proteolipid protein
(PLP); the mRNA for PLP is only located within the perinuclear
cytoplasm, there is no staining of myelin, 950; e–h oligodendrocyte
pathology in transgenic animals overexpressing proteolipid protein;
e and f hemizygous animal, which shows normal myelination, stained
by immunocytochemistry for PLP; in the normal animal PLP protein
is rarely detected in the cytoplasm of oligodendrocytes; in hemizy-
gous PLP transgenic animals a variable extent of PLP expression is
seen in the cytoplasm of oligodendrocytes (e), and this is associated
with aberrant formation of myelin-like structures within and adjacent
to the cells (f); g–h homozygous animal, which shows extensive
dys-myelination; only few oligodendrocytes are preserved, which
are connected to myelin sheaths and contain abundant PLP immuno-
reactivity in their cytoplasm (g); some of the PLP reactive
oligodendrocytes show nuclear condensation and fragmentation,
consistent with apoptosis (h), 91,200; i–o neuropathology of
progressive multifocal leukoencephalopathy; i multiple small conﬂu-
ent demyelinating lesions in the white and gray matter, giving the
impression of a moth eaten pattern of demyelination (92); k edge of
an active demyelinating lesion with numerous macrophages, contain-
ing recent (luxol fast blue positive) degradation products; l and m
pathologically altered nuclei in PML showing giant nuclei of
astrocytes (l) and small oligodendrocyte nuclei with intranuclear
inclusion (m); n and o similar nuclei, as shown in l and m contain
virus antigen as revealed by immunocytochemistry; 91,200
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just one particularly important aspect: data indicating that
also human oligodendrocytes have multiple origins. These
data derive from studies of the human fetal forebrain at
midgestation, and reveal the simultaneous presence of three
different OPC populations [70, 71, 152]. The ﬁrst popula-
tion consists of cortical OPCs which express Dlx2 and
Nkx2.1 [152], typical transcription factors of ventrally
derived OPCs in rodents [72]. The second population
consists of OPCs which do not express Dlx2 and Nkx2.1
and most likely represent dorsally derived oligodendro-
cytes in the human brain [152]. The third population,
ﬁnally, expresses typical OPC markers like PDGFRa,
NG2, and Olig1, and is found in a stream of cells migrating
between the ganglionic eminences and cortical subven-
tricular zone [152]. As in rodents, it remains unclear
whether oligodendrocytes from these different sources
have different roles, myelinate different axonal pathways,
or affect the outcome of CNS pathologies.
Since our knowledge about human oligodendrocyte
biology is limited, results from rodent studies are often
extrapolated to the human situation. However, several
essentialdifferencesbetweentherodentandthehumanbrain
stronglyargueagainstsuchasimpleanduncriticalapproach:
1. Key regions of the human brain might be underdevel-
oped in rodents and vice versa. For example, humans
have neocortical regions which are completely lacking
in mice, while prominent structures of the rodent brain,
the olfactory bulbs, are underdeveloped in humans
[72].
2. The time scale for myelination is different between
humans and rodents. Due to the greater complexity of
the human brain, myelination in the human forebrain
takes decades, compared to weeks in rodents [126].
3. The sheer numbers of oligodendrocytes in humans are
dramatically increased (although the density of oligo-
dendrocytes per mm
3 is remarkably similar between
rodents and humans) [140, 176].
4. Human and rodent OPCs might respond differently to
certain factors [6, 168, 205, 213]. This can be shown
best in the case of CXCL1. Approximately 85% of all
rodent OPCs carry receptors for CXCL1 [37], while
only very few human OPCs do so [47]. Hence, CXCL1
can act directly on rodent OPCs, but has an indirect
mode of action in humans, where it induces astrocytes
to secrete OPC mitogens [47].
Consequences of myelination
Oligodendrocytes not only ensheath axons to electrically
insulate these structures, but also induce a clustering of
sodium channels along the axon, at the node of Ranvier,
which is one important prerequisite for saltatory nerve
conduction [78, 79]. Even normal axonal transport pro-
cesses and neuronal viability seem to depend on proper
myelination, since axons with modiﬁed myelin sheaths
have altered axonal transport rates and changes in the
microtubule number or stability [45, 90], or are swollen
and show signs of degeneration [44, 53, 60, 82, 83, 98,
194]. The presence of intact myelin sheaths could even
lead to an increase in axon diameter [35, 116, 161],
possibly mediated by the local accumulation and phos-
phorylation of neuroﬁlament [161, 162]. And last,
oligodendrocytes can provide trophic support for neurons
by the production of glial cell line-derived neurotrophic
factor (GDNF) [203], brain-derived neurotrophic factor
(BDNF) [41], or insulin-like growth factor-1 (IGF-1)
[42].
Oligodendrocyte metabolism as risk factor
for oligodendrocyte pathology
It has been estimated that during the peak of myelination,
oligodendrocytes elaborate about three times its weight in
membrane per day, and eventually support membrane up to
1009 the weight of its cell body [36, 111, 120, 121]. This
particular feature renders oligodendrocytes vulnerable at
several different ‘‘Achilles0 heels’’.
First, in order to myelinate properly, oligodendrocytes
must have extremely high metabolic rates, and must
consume large amounts of oxygen and ATP [121]. The
production of ATP leads to the formation of hydrogen
peroxide as a toxic byproduct, and a high cellular
metabolism also creates reactive oxygen species, both of
which must be properly metabolized [121]. Second,
myelination is under control of many myelin synthetic
enzymes, which require iron as a co-factor [36]. This may
contribute to the observation that OPCs and oligoden-
drocytes have the largest intracellular stores of iron in the
brain [34, 189], which can, under unfavorable conditions,
evoke free radical formation and lipid peroxidation [18,
76]. On top of this, oligodendrocytes have only low
concentrations of the anti-oxidative enzyme glutathione
[189]. And last, during myelination, the capacity of the
endoplasmic reticulum to produce and fold proteins
properly seems to be a cellular ‘‘bottle neck’’, since even
slight variations in the amount of a single protein can
mess up the entire system and result in the retention,
misfolding, and accumulation of many other proteins in
this oligodendrocytic organelle [10, 16].
Taken together, just being an oligodendrocyte seems
already enough to put these cells at greater risk of damage
under pathological conditions.
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Due to the combination of a high metabolic rate with its
toxic byproducts, high intracellular iron, and low concen-
trations of the antioxidative glutathione, oligodendrocytes
are particularly vulnerable to oxidative damage [76, 189].
Hence, oxidative damage is a common contributor to oli-
godendrocyte loss under many pathological conditions like
MS and ischemia. It can act in concert with the sphingo-
myelinase/ceramide pathway: ceramide is the core
component of sphingolipids, the major lipid components of
myelin sheaths [11]. It is released by the action of sphin-
gomyelinase which is normally inactive, but gets activated
in response to oxidative stress [73, 172], inﬂammatory
mediators [20, 172, 188], injury or infection [165]. Once
released within oligodendrocytes, ceramide can activate
pro-apoptotic signaling cascades eventually culminating in
oligdendrocyte loss [20, 121].
Oligodendrocytes also express an arsenal of molecules
rendering them susceptible to excitotoxic cell death [40,
103, 117, 119, 163]: they carry AMPA [184], kainate [4,
163], and NMDA [80, 123, 160] receptors which make
them vulnerable to glutamate toxicity, and the ATP
receptor P2X7 [118] which predisposes them to the dam-
aging action of sustained levels of extracellular ATP [118].
Oligodendrocyte loss can also occur as a result of
exposure to inﬂammatory cytokines. For example, tumor
necrosis factor a (TNFa) can induce apoptosis of oligo-
dendrocytes by binding to their p55 TNF receptor [75]. The
situation is more complex in the case of interferon gamma
(IFNc). This cytokine is highly toxic for actively prolif-
erating OPCs, much less so for immature oligodendrocytes,
and not at all for mature oligodendrocytes [65]. Besides
these direct actions, inﬂammatory mediators may also
damage oligodendrocytes indirectly through stimulation of
radical production in microglia and possibly also in astro-
cytes. Oxygen- and nitric oxide-radicals are particularly
toxic for mitochondria through interaction and blockade of
various proteins of the respiratory chain [113, 173]. Indeed,
recent studies on changes of gene expression in glia cells
revealed that many different pro-inﬂammatory cytokines
can induce mitochondrial injury [106].
As mentioned above, oligodendrocytes are particularly
vulnerable to oxidative damage and mitochondrial injury.
This is probably reﬂected by the profound oligodendrocyte
damage in certain toxic states, which interfere with mito-
chondrial function. Examples for this are the selective
oligodendrocyte apoptosis and demyelination induced by
cuprizone, a copper chelator interfering with complex IV of
the mitochondrial respiratory chain [191], and by the
intoxication with cyanides also blocking the respiratory
chain at the level of complex IV [27, 63].
All these mechanisms described above do not destroy
oligodendrocytes speciﬁcally, but may also impair function
and viability of other cells, such as neurons and astrocytes.
However, oligodendrocytes and their myelin sheaths are in
general more susceptible to damage than other cellular
components of the nervous system. This explains the so-
called ‘‘bystander damage’’ of myelin and oligodendro-
cytes observed in many inﬂammatory disease states, in
which the immune reaction is not speciﬁcally directed
against these cells [206]. In fact, demyelination and oli-
godendrocyte death is a common feature of inﬂammatory
white matter lesions, both in humans and experimental
models. A particularly illustrative example is Devic’s
neuromyelitis optica (NMO). This disease has originally
been classiﬁed as an inﬂammatory demyelinating disease
due to the presence of widespread primary demyelination
in the spinal cord and optic nerves [110]. Recent immu-
nological studies, however, provide clear evidence that the
primary targets of the pathogenic immune (autoantibody)
response in NMO are not oligodendrocytes, but astrocytes
[100, 101]. Time course studies on lesion development in
NMO patients revealed that astrocytes are destroyed ﬁrst,
but that this is followed by profound demyelination and
oligodendrocyte, axons and nerve cells destruction [127,
128, 158]. Whether oligodendrocyte injury in this disease
is only a bystander reaction of the inﬂammatory process or
whether speciﬁc disturbance of the homeostatic interaction
between astrocytes and oligodendrocytes plays an addi-
tional role, is currently unresolved.
Besides by non-speciﬁc bystander mechanisms, oligo-
dendrocytes can also be destroyed by speciﬁc, cell selective
immune mechanisms. Autoantibodies directed against an
epitope on the extracellular surface of myelin or oligoden-
drocytes can induce demyelination either through activation
of complement or through their recognition by Fc-receptors
of activated macrophages. The most compelling examples
for such autoantibodies are those directed against myelin
oligodendrocyte glycoprotein (MOG, [105]) and galacto-
cerebroside [43]. Antibody-mediated demyelination is an
important mechanism in models of autoimmune encepha-
lomyelitis and seems to play a role also in a subset of
patients with MS-like inﬂammatory demyelinating diseases
[109, 137]. Similarly, cytotoxic T-lymphocytes, directed
against a myelin or oligodendrocyte antigen, or against a
foreign (e.g., virus) antigen expressed in oligodendrocytes,
can induce oligodendrocyte apoptosis, followed by selec-
tive demyelination [66, 130, 164]. As other glia cells and
neurons, oligodendrocytes are able to express major histo-
compatibility (MHC) class I antigens under inﬂammatory
conditions, which is an essential pre-requisition for antigen
recognition and cytotoxicity by MHC class I restricted
cytotoxic T-cells [64].
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reﬂect different pathogenetic mechanisms of myelin
and oligodendrocyte damage
Although pathogenetic events that target myelin and oli-
godendrocytes invariably result in primary demyelination,
the structural patterns of tissue injury in the initial stages of
lesion formation differ, depending upon the mechanism
involved. Three main patterns of tissue injury can be
differentiated.
Simultaneous destruction of oligodendrocytes
and myelin
If the inciting injury is simultaneously directed against
myelin and oligodendrocytes, sharply demarcated plaques
of primary demyelination are induced [180]. Myelin
sheaths are completely lost, while oligodendrocyte cell
bodies may be partly preserved within active lesion areas.
The paradigmatic example for such a mechanism is
demyelination triggered by speciﬁc antibodies against
MOG, an antigen expressed in highest density at the
peripheral processes of oligodendrocytes covering the
myelin sheath [22]. Upon binding of these antibodies,
myelin sheaths are disintegrated by vesicular dissolution in
case of massive complement deposition [54]o rb y
phagocytosis of myelin fragments by macrophages (anti-
body dependent cellular cytotoxicity [21]. Acute injury of
oligodendrocytes follow the pathway of necrosis. However,
mature oligodendrocytes which have lost their myelin
sheaths but survived the initial attack are then slowly
removed from the lesions by apoptosis [208]. Following
these initial changes, sharply demarcated focal demyeli-
nated lesions are formed. A similar pattern of lesion
formation is also seen when myelin and oligodendrocytes
are destroyed through antigen-speciﬁc cytotoxic T-cells
[164] or non-selectively by toxic products of activated
macrophages (bystander demyelination). Under the latter
conditions, however, the demyelinated lesions are associ-
ated with much more widespread damage to other cellular
components as well, in particular axons.
Primary oligodendrocyte injury
Distinct types of lesions are seen, when the primary injury
is due to a metabolic disturbance of oligodendrocytes, not
directly affecting myelin. In this situation, demyelination is
frequently incomplete. Such lesions not only contain areas
of complete demyelination, but also diffuse myelin pallor
is observed. At the edges of the lesions, a moth eaten
pattern of demyelination is observed which may reﬂect the
loss of single oligodendrocytes with their respective myelin
sheaths. This pattern of demyelination is mainly seen in
conditions of infections, which target oligodendrocytes,
such as progressive multifocal leukoencephalopathy. In
such conditions, virus antigen is abundant in oligodendro-
cytes and the cells are destroyed both by apoptosis or
necrosis [129]. Toxic damage of oligodendrocytes, for
example by cuprizone results in similar patterns of demy-
elination [191].
Demyelination and oligodendrocyte damage induced
by mitochondrial injury and/or energy deﬁciency
Energy deﬁciency in the white matter leads to a funda-
mentally different pattern of tissue injury. Also in this
condition, oligodendrocytes are highly vulnerable, but they
die by a process termed ‘‘distal/dying back oligodendro-
gliopathy’’. In initial lesions, the most severely damaged
parts of the cells are the most distal (periaxonal) oligo-
dendrocyte processes [1]. This is reﬂected by a selective
loss of proteins, which are predominantly located in this
location, such as myelin-associated glycoprotein (MAG)
Fig. 2 Myelin and oligodendrocyte pathology in autoimmune
encephalomyelitis, multiple sclerosis, and stroke. a–d Chronic
autoimmune encephalomyelitis, induced in DA rat by active sensi-
tization with MOG fusion protein; a massive demyelination is seen in
the cerebellar white matter, 96; b–d oligodendrocytes in different
lesion stages of EAE; in the peri-plaque white matter myelin (red)i s
present and multiple oligodendrocytes with PLP mRNA (black) are
seen (b); in the active lesions myelin falls apart, myelin fragments are
taken up by macrophages (red granules) and oligodendrocytes are lost
(c); in more advanced lesions no macrophages with early myelin
degradation products are present; numerous oligodendrocytes re-
appear in the lesions, apparently recruited from progenitor cells (black
cells), followed by rapid and extensive remyelination; immunocyto-
chemistry for PLP and in situ hybridization for PLP mRNA, 91000;
e–h chronic multiple sclerosis case with extensive remyelination
within the CNS; This hemispheric brain section contains 3 active
lesions, 4 demyelinated plaques, and 8 remyelinated shadow plaques,
91.2; f–h double staining for PLP protein (red) and PLP mRNA
(black) in one of the active lesions shows a similar pattern as
described before in EAE; many oligodendrocytes in the peri-plaque
white matter (f); oligodendrocyte loss in the zone of active
demyelination (g) and reappearance of oligodendrocytes in the
inactive zone, closely adjacent to the zone of activity (h), 9500;
i–o myelin changes in the initial stage of a lesion in white matter
stroke; LFB shows pale myelin staining (i); the axons, stained with
Bielschowsky silver impregnation are largely preserved (k); MAG (l)
and CNPase (m) are completely lost from the lesions, while the
myelin proteins within the compact sheath (PLP; n) or on the
oligodendrocyte surface (MOG; o) are preserved, 920; p–s acute
multiple sclerosis with lesions following a pattern of hypoxia-like
tissue injury (Pattern III, [109]). p The section contains areas of initial
demyelination (i), early active demyelination (a) and late active or
inactive portions (d); q serial section of p, stained by immunocyto-
chemistry for PLP; Only the late active and inactive lesions show loss
of PLP; in the active portions (a) a minor loss of PLP reactivity is
seen, while in the initial lesions PLP reactivity is the same as in the
normal appearing white matter, 93; r and s edge of an active lesion
showing partial preservation of immunoreactivity for MOG (r), but
extensive and complete loss of MAG(s), 920
c
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123and cyclic nucleotide phosphodiester [1, 68]. Conventional
staining for myelin with luxol fast blue shows a diffuse or
focal myelin pallor, while immunocytochemistry for pro-
teins located within compact myelin (myelin basic protein
or proteolipid protein) is unaffected. With progression of
the lesions the majority of oligodendrocytes reveal nuclear
condensation and in part nuclear fragmentation in the
absence of the expression of activated caspase 3 (caspase
independent apoptotic like cell death). Additional charac-
teristic features of such lesions are the preferential
destruction and loss of small caliber axons and a remark-
able preservation of axons and myelin around larger blood
vessels (arterioles and veins). Such tissue changes are the
hallmark of initial ischemic lesions of the white matter, and
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123occur within the ﬁrst hours or days in a white matter stroke
lesion [1]. Similar lesions, however, can also be seen in
severe inﬂammatory brain lesions, for example in a subset
of patients with acute multiple sclerosis or with virus
infections of the white matter like herpes simplex virus
encephalitis, cytomegalovirus encephalitis, or progressive
multifocal leukoencephalopathy [1]. In the latter lesions,
energy deﬁciency is associated with profound mitochon-
drial damage, which may at least in part be induced by
disturbance of the mitochondrial respiratory chain through
reactive oxygen and nitrogen species [114]. Upregulation
of molecules which are induced by (hypoxic) tissue pre-
conditioning, such as hypoxia inducible factor 1 alpha or
stress proteins in the periphery of such lesions may exert
local neuroprotective effects. Moreover, tissue areas with
increased resistance to energy deﬁciency may alternate in
the periphery of the lesions with more vulnerable areas,
and can give rise to concentric layering of demyelinated
and preserved tissue zones typically found in the lesions of
Balo’s type of concentric sclerosis [175] (Fig. 2).
It has to be emphasized that these distinct patterns of
demyelination segregate well in the initial stages of lesion
formation and in patients with rapidly progressive white
matter disease. However, in more slowly expanding
lesions, these morphological features may in part be lost.
Then, it may become difﬁcult to determine the mecha-
nism of tissue injury purely on morphological grounds.
The ﬁnal outcome of all the lesions described above is
focal or diffuse areas of primary demyelination in the
white matter.
Remyelination
Remyelination, the restoration of new myelin sheaths to
demyelinated axons, is not performed by pre-existing
mature oligodendrocytes [84, 144, 170, 185], but involves
in most cases the generation of new mature oligodendro-
cytes from the adult, quiescent OPC pool distributed
throughout the CNS [28, 46, 56, 61, 102, 136, 200, 201,
212]. In the corpus callosum, remyelinating oligodendro-
cytes can also be derived from stem and precursor cells of
the adult subventricular zone [50, 131]. The process of
remyelination takes place in several different steps. First,
local adult OPCs must switch from an essentially quiescent
state to a regenerative phenotype [50]. This transition
seems to be triggered by factors derived from activated
microglia cells and astrocytes [57, 156], and not by the
demyelination per se [134], and leads to OPC proliferation
and recruitment to demyelinated areas [50]. Then, the
differentiation of OPCs to remyelinating oligodendrocytes
starts. All following steps—the interactions with unmy-
elinated axons, the expression of myelin genes, the
elaboration, wrapping and compacting of myelin mem-
brane to form myelin sheaths are similar in myelinating
OPCs during development, and in remyelinating OPCs
during the regenerative process [50]. However, some dif-
ferences between myelination and remyelination exist:
1. Adult OPCs have a longer cell cycle time and a slower
rate of migration [209].
2. The requirements for transcription factor usage seem
to be different. Studies in genetically modiﬁed mice
clearly revealed that the lack of the oligodendrocyte-
lineage speciﬁc transcription factor olig1 is incompat-
ible with myelination of the brain [210]. However,
when this lack is compensated by the overexpression
of the oligodendrocyte-lineage speciﬁc transcription
factor olig2 (as was probably the case in earlier
studies, due to the usage of a particular gene targeting
cassette [107, 210]), the mice were able to myelinate
during development [7], but were unable to repair
demyelinated lesions by remyelination [7].
3. Notch, the regulator of oligodendrocyte differentiation
in development (see above), is dispensable during
remyelination [179].
4. The correlation between axon diameter and myelin
sheath thickness and length seen during developmental
myelination is less apparent in remyelination, resulting
in thinner and shorter sheath segments [50, 112]. The
mechanisms underlying this observation remain
unclear, but could involve signals obtained from
dynamically growing and changing axons with a need
for myelination along their entire length during
development, or from mature axons focally lacking
myelin sheaths during remyelination [50].
Thus, the pathological hallmark of remyelination in the
CNS is the presence of axons with unusually thin myelin
sheaths in relation to their caliber [182]. This is best seen
by an increase of the G-ratio (the ratio between axonal
diameter and myelinated ﬁber diameter). Unequivocal
identiﬁcation of remyelination in conditions of diffuse
demyelination is possible at early stages, but very difﬁcult
in older established lesions. In the latter situation detailed
quantitative electron microscopic studies may be necessary
to show differences in the G-ratio in affected areas. In areas
of focal demyelination, such as those occurring in multiple
sclerosis, remyelination is reﬂected by shadow plaques
(Markschattenherde, [166]). These are MS-typical focal,
sharply demarcated white matter lesions, characterized by
uniformly thin myelin sheaths [149].
Remyelination has been extensively studied in MS. In
accordance with the basic concepts described above, the
recruitment of OPCs and early remyelination is extensive
in very early stages of demyelination, in lesions which are
still inﬁltrated by macrophages and lymphocytes [99, 147,
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123151], and in plaques formed at early stages of the disease.
In these fresh lesions, remyelination might be facilitated by
inﬂammation and inﬁltrating macrophages which provide
the tissue with growth factors [39, 92]. Remyelination
largely fails at the later (progressive) stage of the disease
[59]. This failure of remyelination may be additionally
ascribed to age [153, 169], to age-associated changes in the
growth factor responsiveness of adult OPCs, and to less
efﬁcient clearance of myelin debris from the lesions which
has been shown to inhibit remyelination in experimental
models [93, 169]. Progressive axonal loss in the lesions, an
inability of demyelinated axons to interact with myelinat-
ing cells [33], or the presence of myelination inhibiting
factors in the extracellular space [204] may additionally
impair the capacity of remyelination. These speculations
are further corroborated by the observations that mature
oligodendrocytes found in active lesions slowly disappear
from established lesions [208], and that the OPCs found in
late demyelinated lesions seem to be impaired in their
further differentiation to mature myelin forming oligo-
dendrocytes [31, 94]. Moreover, it has also been observed
that both the numbers and the differentiation stages of
OPCs and mature oligodendrocytes are highly variable
within lesions of different patients and in different lesion
stages. This suggests that different mechanisms of demy-
elination may have different effects on the remyelinating
capacity of lesions [108].
Thus, major efforts are invested to ﬁnd new neuropro-
tective therapies, which stimulate myelin repair and by this
halt progressive degeneration of chronically demyelinated
axons. However, recent studies suggest that the situation in
MS patients might be more complicated than previously
anticipated. These studies show that extensive remyelina-
tion is even seen in a subset of patients, who died at the late
progressive stage of the disease. The extent of remyelina-
tion in these patients was variable, depending upon the
location of the plaques in the brain and spinal cord [142,
143]. Extensive remyelination was predominantly seen in
forebrain lesions, located in the subcortical and deep white
matter, while it was rather sparse in periventricular areas,
the brain stem, and the spinal cord. These data indicate that
the capacity of OPCs to differentiate into remyelinating
cells is regionally different, possibly related to intrinsic
differences in different oligodendrocyte populations as
discussed above.
Another important factor is the instability of newly
formed myelin in MS lesions, which still show inﬂamma-
tory and demyelinating activity. New demyelinating
activity in previously remyelinated shadow plaques has
been unequivocally documented in MS [148], and areas of
remyelination are more frequently affected by new
inﬂammatory demyelination than the normal appearing
white matter [17]. However, the instability of newly
formed myelin in MS lesions also crucially depends on an
active inﬂammatory environment. When inﬂammation
subsides at very late stages of the disease [51], myelin
repair seems to be long lasting and stable [143].
Conclusions
Oligodendrocyte biology, myelination, and maintenance of
myelin sheaths are very complex processes and their dis-
turbances are associated with major diseases of the nervous
system. Intensive research efforts, performed during the
last decades have clariﬁed basic principles of these pro-
cesses and offer new avenues for therapeutic interventions.
Much less, however, is known so far on the exact role of
these processes in the different diseases of the nervous
system. Addressing these questions will be the major
challenge for the near future.
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Appendix 1: Heterogeneity among adult OPCs
The adult OPCs express the proteoglycan NG2 and the
PDGF receptor a [30, 85, 154, 170], and have been
given numerous names like NG2-expressing OPCs [50],
synantocytes [24], or polydendrocytes [135]. Current
experimental evidence suggests that they might be less
restricted in their differentiation potential and might not
only give rise to oligodendrocytes, but also to neurons in
the hippocampus [12] or to astrocytes [5, 29]. They are
probably not only heterogenous in terms of the different
cell types they can give rise to, but also seem to be het-
erogenous in function: while some of them become
quiescent, others apparently have key physiological roles
and are involved in the bi-directional communication
between glial cells and neurons since they receive synaptic
inputs [14, 69, 80, 95, 215] and are able to generate action
potentials [81].
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